These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 4358481)

  • 21. Differential extraction of tumor-specific transplantation antigen and embryonic antigen from simian virus 40- and adenovirus 7-induced sarcoma cells of hamsters with 1-butanol and 3 M potassium chloride.
    Coggin JH; Gillis LD; Payne WJ
    J Natl Cancer Inst; 1984 Apr; 72(4):853-62. PubMed ID: 6323810
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antitumor effects of antibody-diphtheria toxin conjugates. II. Immunotherapy with conjugates directed against tumor antigens induced by simian virus 40.
    Moolten FL; Capparell NJ; Zajdel SH; Cooperband SR
    J Natl Cancer Inst; 1975 Aug; 55(2):473-7. PubMed ID: 169378
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prospects and limitations of recombinant poxviruses for prostate cancer immunotherapy.
    Hwang C; Sanda MG
    Curr Opin Mol Ther; 1999 Aug; 1(4):471-9. PubMed ID: 11713762
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A marked sex difference in the immunization capability of hamsters towards a mouse tumour.
    Kinsky RG
    Ann Immunol (Paris); 1974; 125(3):439-43. PubMed ID: 4411652
    [No Abstract]   [Full Text] [Related]  

  • 25. The delayed and lasting rejection of mammary adenocarcinoma cell tumors in DBA-2 mice with use of killed Bordetella pertussis.
    Likhite VV
    Cancer Res; 1974 May; 34(5):1027-30. PubMed ID: 4363061
    [No Abstract]   [Full Text] [Related]  

  • 26. Immunogenic properties of a soluble tumor rejection antigen (TSTA) from a Simian virus 40-induced sarcoma.
    Rogers MJ; Law LW
    Int J Cancer; 1979 Jan; 23(1):89-96. PubMed ID: 83307
    [No Abstract]   [Full Text] [Related]  

  • 27. Simian virus 40 large-T-antigen-specific rejection of mKSA tumor cells in BALB/c mice is critically dependent on both strictly tumor-associated, tumor-specific CD8(+) cytotoxic T lymphocytes and CD4(+) T helper cells.
    Utermöhlen O; Schulze-Garg C; Warnecke G; Gugel R; Löhler J; Deppert W
    J Virol; 2001 Nov; 75(22):10593-602. PubMed ID: 11602701
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Radiation-induced changes in established tumor immunity.
    Vaage J; Doroshow JH; DuBois TT
    Cancer Res; 1974 Jan; 34(1):129-37. PubMed ID: 4809453
    [No Abstract]   [Full Text] [Related]  

  • 29. Immunotherapy of tumor-bearing mice with chemically modified tumor membrane fractions of two syngeneic tumor cell lines.
    Staab HJ; Anderer FA
    Cancer Detect Prev; 1984; 7(4):279-88. PubMed ID: 6091881
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Priming of naive T cells inside tumors leads to eradication of established tumors.
    Yu P; Lee Y; Liu W; Chin RK; Wang J; Wang Y; Schietinger A; Philip M; Schreiber H; Fu YX
    Nat Immunol; 2004 Feb; 5(2):141-9. PubMed ID: 14704792
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prospects for tumor immunotherapy in man, with emphasis on its use as an adjunct to surgery for primary operable cancer.
    Southam CM
    J Med Liban; 1975; 28(1):43-66. PubMed ID: 1107552
    [No Abstract]   [Full Text] [Related]  

  • 32. Protection of mice from malignant tumor implants by enucleated tumor cells.
    Sethi KK; Brandis H
    J Natl Cancer Inst; 1974 Oct; 53(4):1175-6. PubMed ID: 4372368
    [No Abstract]   [Full Text] [Related]  

  • 33. Proceedings: Immunologic similarities between fetal cell antigens and tumor cell antigens in guinea pigs.
    Grant JP; Ladisch S; Wells SA
    Cancer; 1974 Feb; 33(2):376-83. PubMed ID: 4812757
    [No Abstract]   [Full Text] [Related]  

  • 34. Antitumor effects of antibody-diphtheria toxin conjugates: use of hapten-coated tumor cells as an antigenic target.
    Moolten FL; Capparell NJ; Cooperband SR
    J Natl Cancer Inst; 1972 Oct; 49(4):1057-62. PubMed ID: 4343471
    [No Abstract]   [Full Text] [Related]  

  • 35. Active vaccination after allogeneic bone marrow cell transplantation: a new option in the immunotherapy of cancer?
    Zöller M; Matzku S
    Arch Immunol Ther Exp (Warsz); 2002; 50(3):197-224. PubMed ID: 12098935
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Radiocurability of a transplantable murine sarcoma as influenced by immune competence of the host and adjuvant active specific immunotherapy.
    Deneufbourg JM
    Strahlentherapie; 1975 Apr; 149(4):457-62. PubMed ID: 237344
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rejection of MHC class II-transfected tumor cells requires induction of tumor-encoded B7-1 and/or B7-2 costimulatory molecules.
    Baskar S; Clements VK; Glimcher LH; Nabavi N; Ostrand-Rosenberg S
    J Immunol; 1996 May; 156(10):3821-7. PubMed ID: 8621919
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tumor immunity in vivo: evidence that immune destruction of tumor leaves "bystander" cells intact.
    Weissman IL
    J Natl Cancer Inst; 1973 Aug; 51(2):443-8. PubMed ID: 4765368
    [No Abstract]   [Full Text] [Related]  

  • 39. Concomitant immunity and specific desensitization in murine tumor hosts.
    Vaage J
    Isr J Med Sci; 1973 Mar; 9(3):332-43. PubMed ID: 4710041
    [No Abstract]   [Full Text] [Related]  

  • 40. Early vaccination with tumor-lysate-pulsed dendritic cells after allogeneic bone marrow transplantation has antitumor effects.
    Moyer JS; Maine G; Mulé JJ
    Biol Blood Marrow Transplant; 2006 Oct; 12(10):1010-9. PubMed ID: 17084367
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.